GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Emmaus Life Sciences Inc (OTCPK:EMMA) » Definitions » Cyclically Adjusted PB Ratio

Emmaus Life Sciences (Emmaus Life Sciences) Cyclically Adjusted PB Ratio : (As of Jun. 01, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Emmaus Life Sciences Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Emmaus Life Sciences Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Emmaus Life Sciences's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emmaus Life Sciences Cyclically Adjusted PB Ratio Chart

Emmaus Life Sciences Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Emmaus Life Sciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Emmaus Life Sciences's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Emmaus Life Sciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Emmaus Life Sciences's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Emmaus Life Sciences's Cyclically Adjusted PB Ratio falls into.



Emmaus Life Sciences Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Emmaus Life Sciences's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2023 is calculated as:

For example, Emmaus Life Sciences's adjusted Book Value per Share data for the three months ended in Sep. 2023 was:

Adj_Book=Book Value per Share/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.677/129.8595*129.8595
=-0.677

Current CPI (Sep. 2023) = 129.8595.

Emmaus Life Sciences Quarterly Data

Book Value per Share CPI Adj_Book
201312 -10.406 98.326 -13.743
201403 -6.063 99.695 -7.898
201406 -16.146 100.560 -20.850
201409 -20.798 100.428 -26.893
201412 -30.123 99.070 -39.485
201503 -37.169 99.621 -48.451
201506 -43.000 100.684 -55.460
201509 -56.673 100.392 -73.308
201512 -77.950 99.792 -101.436
201603 -77.255 100.470 -99.853
201606 -83.419 101.688 -106.529
201609 -3.292 101.861 -4.197
201612 2.041 101.863 2.602
201703 1.251 102.862 1.579
201706 -2.252 103.349 -2.830
201709 6.346 104.136 7.914
201712 2.931 104.011 3.659
201803 2.524 105.290 3.113
201806 2.984 106.317 3.645
201809 3.256 106.507 3.970
201812 1.719 105.998 2.106
201903 1.359 107.251 1.645
201906 1.795 108.070 2.157
201909 -0.368 108.329 -0.441
201912 -0.228 108.420 -0.273
202003 -0.097 108.902 -0.116
202006 -0.286 108.767 -0.341
202009 -0.130 109.815 -0.154
202012 -0.105 109.897 -0.124
202103 -0.257 111.754 -0.299
202106 -0.190 114.631 -0.215
202109 -0.306 115.734 -0.343
202112 -0.435 117.630 -0.480
202203 -0.452 121.301 -0.484
202206 -0.699 125.017 -0.726
202209 -0.758 125.227 -0.786
202212 -0.688 125.222 -0.713
202303 -0.706 127.348 -0.720
202306 -0.653 128.729 -0.659
202309 -0.677 129.860 -0.677

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Emmaus Life Sciences  (OTCPK:EMMA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Emmaus Life Sciences Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Emmaus Life Sciences's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Emmaus Life Sciences (Emmaus Life Sciences) Business Description

Traded in Other Exchanges
N/A
Address
21250 Hawthorne Boulevard, Suite 800, Torrance, CA, USA, 90503
Emmaus Life Sciences Inc is a biopharmaceutical company engaged in the discovery, development, and commercialization of new treatments and therapies primarily for rare and orphan diseases. The company's commercial product is Endari, an oral pharmaceutical grade L-glutamine treatment indicated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Its products in the pipeline include Diverticulosis and Cell Sheet Engineering.
Executives
Seah H. Lim director 21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503
Willis C Lee director, officer: Vice Chairman & COO 20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501
Yutaka Niihara director, 10 percent owner, officer: Chairman and CEO 20725 S. WESTERN BLVD., SUITE 136, TORRANCE CA 90501
Lori Teranishi director 1000 BISHOP STREET, SUITE 500, HONOLULU HI 96813
Charles William Stark officer: SVP, Clinical Development 21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
George Sekulich officer: CIO & SVP 21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
Lui Alfred Fu Kong director 21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
Jane Pine Wood director 956 MAIN STREET, DENNIS MA 02638
Wei Peu Zen director 21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503
Sherwood Joseph Charles Iii officer: Chief Financial Officer 21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503
Masaharu Osato director 3440 LOMITA BOULEVARD, SUITE 320, TORRANCE CA 90505
Ian Harvey Zwicker director 21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
Lan T. Tran officer: Chief Administrative Officer 20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501
Robert Iv Dickey director 320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Yasushi Nagasaki officer: Sr. VP Finance 20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501